n-3 Fatty acid supplementation and proresolving mediators of inflammation

Current Opinion in Lipidology

Volumn 27, Issue 1, 2016, Pages 26-32

  Barden, Anne E ^a   Mas, Emilie ^a   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

inflammation; maresins; n 3 fatty acids; protectins; resolvins

Indexed keywords

AUTACOID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; UNSATURATED FATTY ACID;

ANIMAL; HUMAN; INFLAMMATION; METABOLISM;

ANIMALS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84954383390     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000262     Document Type: Review

References (34)

1. Mori TA. Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food Funct. 2014; 5: 2004-2019. Comprehensive review of the role of n-3 fatty acids in CVD
2. Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015; 1851: 469-484. Overview of the role of n-3 fatty acids in inflammation
3. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004; 6: 461-467.
4. Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harbor Perspect Biol. 2014; 7: a016311. Up-To-date comprehensive review of lipid mediators of the resolution of inflammation: biosynthesis and actions in humans and disease models
5. Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014; 19: 21-36.
6. Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17, 18-dihydroxyeicosapentaenoic acid. J Biol Chem. 2012; 287: 10525-10534.
7. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011; 111: 5922-5943.
8. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010; 107: 1170-1184.
9. Deng B, Wang C-W, Arnardottir HH, et al. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PloS One. 2014; 9: e102362. Describes the biosynthesis and structure elucidation of maresin 2 as a novel lipid mediator from human macrophages
10. Serhan CN, Dalli J, Karamnov S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 2012; 26: 1755-1765.
11. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015; 27: 200-215. Reviews the biosynthesis and actions lipid mediators of the resolution of inflammation
12. Arita M, Ohira T, Sun Y-P, et al. Resolvin E1 selectively interacts with leukotriene B-4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007; 178: 3912-3917.
13. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012; 180: 2018-2027.
14. Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015; 212: 1203-1217.
15. Hasturk H, Abdallah R, Kantarci A, et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015; 35: 1123-1133.
16. Kain V, Ingle KA, Colas RA, et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Molec Cell Cardiol. 2015; 84: 24-35.
17. Endo J, Sano M, Isobe Y, et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med. 2014; 211: 1673-1687.
18. Chiu CY, Gomolka B, Dierkes C, et al. Omega-6 docosapentaenoic acidderived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. Inflamm Res. 2012; 61: 967-976.
19. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol. 2012; 189: 1036-1042.
20. Norling LV, Spite M, Yang R, et al. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol. 2011; 186: 5543-5547.
21. Mas E, Croft KD, Zahra P, et al. Resolvins D1, D2, and other mediators of selflimited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem. 2012; 58: 1476-1484.
22. Ramsden CE, Faurot KR, Zamora D, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013; 154: 2441-2451.
23. Barden A, Mas E, Croft KD, et al. Short-Term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res. 2014; 55: 2401-2407. Describes lipid mediators of inflammation in human plasma from a randomized controlled trial of aspirin in the setting of n-3 fatty acid supplementation
24. Mas E, Barden A, Burke V, et al A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr. 2015; doi: 101016/jclnu201504004 [Epub ahead of print
25. Keelan JA, Mas E, D Vaz N, et al. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. Reproduction. 2015; 149: 171-178.
26. Skarke C, Alamuddin N, Lawson JA, et al. Bioactive products formed from fish oils. J Lipid Res. 2015; 56: 1808-1820.
27. Dawczynski C, Massey KA, Ness C, et al. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Clin Nutr. 2013; 32: 686-696.
28. Grenon SM, Owens CD, Nosova EV, et al. Short-Term, high-dose fish oil supplementation increases the production of omega-3 fatty acid derived mediators in patients with peripheral artery disease (the OMEGA-PAD 1 Trial). J Am Heart Assoc. 2015; 4: e002034.
29. Xu ZZ, Zhang L, Liu T, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med. 2010; 16: 592-597.
30. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013; 3: 957-976.
31. Yokokura Y, Isobe Y, Matsueda S, et al. Identification of 14, 20-dihydroxydocosahexaenoic acid as a novel anti-inflammatory metabolite. J Biochem. 2014; 156: 315-321.
32. Dalli J, Colas RA, Serhan CN. Novel n-3 immunoresolvents: structures and actions. Sci Rep. 2013; 3: 1940.
33. Dalli J, Chang N, Serhan CN. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat Med. 2015; 21: 1071-1075. First description of the biosynthesis, structural elucidation, and actions of DPAderived lipid mediators of inflammation resolution
34. Abdelmagid SA, Clarke SE, Nielsen DE, et al. Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PloS One. 2015; 10: e0116195.